Targeting the nucleolus for cancer intervention  by Quin, Jaclyn E. et al.
Biochimica et Biophysica Acta 1842 (2014) 802–816
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReviewTargeting the nucleolus for cancer intervention☆Jaclyn E. Quin a,b, Jennifer R. Devlin a,b, Donald Cameron a, Kate M. Hannan a,b,
Richard B. Pearson a,b,c,d, Ross D. Hannan a,b,c,d,e,f,⁎
a Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
b Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, Victoria, Australia
c Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
d Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia
e Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia
f School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland, AustraliaAbbreviations:DDR, DNA Damage Response; DSB, Dou
Radiation; NAD, Nucleolus Associated Domain; NCL, Nucl
Region; NPM, Nucleophosmin; PIC, Pre-Initiation Compl
Polymerase I; Pol II, DNA-dependent RNA Polymerase I
Polymerase I; rDNA, ribosomal RNA genes; RNP, Ribo
Protein; rRNA, ribosomal RNA; S6K, ribosomal protein S6
plex; snRNP, small nucleolar Ribonucleoprotein; TTF-1, P
Factor; UBF, Upstream Binding Factor; Xi, inactive X chrom
☆ This article is part of a Special Issue entitled: Role of th
⁎ Corresponding author at: Oncogenic Signalling and
MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Mel
E-mail address: ross.hannan@petermac.org (R.D. Hann
0925-4439/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2013.12.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 28 October 2013
Accepted 17 December 2013







MYCThe contribution of the nucleolus to cancer is well established with respect to its traditional role in facilitating
ribosome biogenesis and proliferative capacity. More contemporary studies however, infer that nucleoli
contribute a much broader role in malignant transformation. Speciﬁcally, extra-ribosomal functions of the
nucleolus position it as a central integrator of cellular proliferation and stress signaling, and are emerging as
importantmechanisms for modulating how oncogenes and tumor suppressors operate in normal andmalignant
cells. The dependence of certain tumor cells to co-opt nucleolar processes to maintain their cancer phenotypes
has now clearly been demonstrated by the application of small molecule inhibitors of RNA Polymerase I to
block ribosomal DNA transcription and disrupt nucleolar function (Bywater et al., 2012 [1]). These drugs,
which selectively kill tumor cells in vivo while sparing normal cells, have now progressed to clinical trials. It is
likely thatwe have only just begun to scratch the surface of the potential of the nucleolus as a new target for can-
cer therapy, with “suppression of nucleolar stress” representing an emerging “hallmark” of cancer. This article is
part of a Special Issue entitled: Role of the Nucleolus in Human Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Over 200 years ago the development of light microscopy led to the
revelation that cells are not ﬁxed entities but dynamically responsive
to environmental cues. This was exempliﬁed with the observation that
the most prominent structure within the nucleus, the nucleolus,
disassembles and then reassembles during each cell cycle. Today it is
well established that the nucleolus acts as a hub coordinating the
synthesis and assembly of the core protein synthesizing machinery of
the cell, the ribosome. In mammals this entails transcription by the
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ights reserved.genes (rDNA) that give rise to the 47S ribosomal RNA (rRNA) precursor,
which is subsequently processed into the mature 28S, 18S and 5.8S
rRNA. These rRNAs, together with the 5S rRNA synthesized by RNA
polymerase III (Pol III) and the numerous ribosomal proteins (RPs)
encoded by RNA polymerase II (Pol II) transcribed genes, are then as-
sembled within the nucleolus into the 40S and 60S ribosomal subunits
before export to the cytoplasm (reviewed in [2]). The nucleolus, while
not membrane bound, represents a discrete yet dynamic structural do-
mainwithin the nucleus intowhich various proteins can be sequestered
and released. Its assembly and disassembly is a result of its dependence
upon Pol I transcription, as nucleoli form around actively transcribing
rDNA repeats (reviewed in [3,4]). Intriguingly, recent studies demon-
strate that eukaryotic cells have evolved to use the nucleolar domain
for an extensive and varied repertoire of cellular activities in addition
to ribosome biogenesis. Additional roles now ascribed to the nucleolus
include modulation of the cellular stress response, regulation of senes-
cence and cell cycle progression, RNA and ribonucleoprotein (RNP)
biogenesis, and even organization of the epigenome (see Section 4).
A strong correlation between nucleolar morphology and cancer was
recognized by pathologists over 100 years ago, when it was ﬁrst
observed that large and abnormal nucleoli were common in cancer
cells [5]. More contemporary studies have demonstrated that the
dysregulated nucleolar morphology reﬂects hyperactivation of rDNA
transcription (reviewed in [6]). For the larger part, it has been considered
803J.E. Quin et al. / Biochimica et Biophysica Acta 1842 (2014) 802–816that the primary function of accelerated ribosome biogenesis in cancer is
to simply enable the increased proliferative growth frequently associated
with malignancies. However, recent studies strongly suggest that the
ability of the nucleolus to regulate non-ribosomal functions, in particular
controlling the activity of various critical tumor suppressors and
oncogenes, is likely to contribute signiﬁcantly to malignant transforma-
tion. For example, it is now evident that impairing any one of a number
of steps in ribosome biogenesis leads to activation of a nucleolar stress/
surveillance mechanism that can result in the accumulation of the
tumor suppressor protein p53 (reviewed in [7–9]). The direct coupling
of ribosome biogenesis to proliferative and stress signaling pathways
makes evolutionary sense: cells must on the one hand ensure sufﬁcient
protein synthetic capacity prior to committing to cell cycle progression;
on the other, they need to reduce the enormous energy expended in
making ribosomes if they are not undergoing division. Thus, for example,
p53 is activated in response to impairment of ribosome biogenesis, or
conversely suppressed by increased ribosome biogenesis driven by
proto-oncogenic growth and survival signals [10].
These observations have led to the proposal that acute inhibition
of ribosome biogenesis could form the basis of a tumor-speciﬁc
mechanism to non-genotoxically activate p53, for cancer therapy. This
hypothesis has been tested by Bywater et al., who reported that the
small molecule inhibitor of Pol I transcription, CX-5461, killed B-cell
lymphoma cells in vivo, while sparing the normal B-cell population
[1]. These data provided the ﬁrst direct evidence that targeting a
nucleolar process (i.e. rDNA transcription) was a viable strategy for
cancer therapy, and has led to a Phase 1 clinical trial of CX-5461 in
patients with hematologic malignancies commenced in 2013 (Peter
MacCallum Cancer Centre, Melbourne). The focus of this review is to
evaluate the current understanding of the role of the nucleolus in cancer
and to discuss how it can be targeted as a novel cancer treatment.
2. Regulation of the nucleoli
Eukaryotic cells typically contain multiple nucleoli per nucleus,
which form around active clusters of the 47S rRNA genes (rDNA)
known as the nucleolus organizer regions (NORs). There are ~200
copies of the rRNA gene located in tandem arrays at 5 locations in the
genome, on the short arms of the acrocentric chromosomes; only a
proportion of these (approximately half) are transcriptionally compe-
tent, with an ‘open’ structure associated with euchromatic histone
modiﬁcations (H4Ac and H3K4Me), while the rest are transcriptionally
silenced, with a heavily CpG methylated heterochromatic structure
(H3K9Me, HK27Me and H3K20Me) (reviewed in [11–15]). Transcrip-
tionally competent rDNA repeats are not necessarily active, but those
that are characterized by association with the transcription factor UBF
can achieve very high rates of transcription by Pol I [16], accounting
for N30% of transcriptional activity of an exponentially growing cell
[17] and [12].
Although the nucleoli are not membrane bound organelles, they
segregate into three distinct regions: the pale-staining ﬁbrillar center
(FC), surrounded by the compact dense ﬁbrillar component (DFC),
which in turn is encased by an outer granular compartment (GC)
(reviewed in [3] and [4]). These regions can also be deﬁned by their
afﬁliated proteins or RNA, and as such the processes functioning within
these zones. Production of the rRNA requires formation of a competent
pre-initiation complex (PIC) - comprising the regulatory factors UBF,
RRN3 and the selectivity complex (SL-1) - at the promoter of the active
rDNA genes, and subsequent transcription of the 47S precursor rRNA by
Pol I (reviewed in [18–20]). These elements are concentrated at the
boundary of the FC and DFC. The newly synthesized 47S precursor is
extensively processed by splicing and post-translational modiﬁcation,
the early stages of which occur in the DFC, and the later stages in the
peripheral GC. The GC contains the highest density of proteins due to
it also being the location of assembly of the mature rRNAs along
with the RPs into the 40 and 60S ribosome subunits. In addition, theepigenetically silent rDNA repeats associate with a shell of heterochro-
matin that surrounds the nucleolus (perinucleolar heterochromatin).
Hence, the structure and biological functions of the nucleoli aremutual-
ly dependent (Fig. 1).
Importantly, nucleoli are dynamic in nature, and exquisitely regulat-
ed by multiple signaling pathways that primarily converge directly
upon the Pol I transcription factors, such as PIC components RRN3,
UBF and SL-1. This enables the nucleoli to respond rapidly to changing
proliferative or environmental cues — a far cry from early studies that
suggested rDNA transcription responded slowly and indirectly to
nutrient status (reviewed in [21]). During the cell cycle, themammalian
nucleoli disassemble at the start of mitosis (prophase), coinciding with
the inactivation of rDNA transcription; nucleoli then reassemble during
telophase in a precisely controlled manner, enabling reactivation of
rDNA transcription as cells enter G1. Rates of rDNA transcription are
also increased during S and G2, as cells grow in preparation for cell
division. This is achieved through the direct regulation of Pol I transcrip-
tion factors by cell cycle regulatory proteins [22–25]. Further to cell
cycle regulation, control of the rate of Pol I transcription is mediated
by additional signaling pathways that control cell growth and division
(reviewed in [20,26]). Broadly, these can be separated into those that
upregulate ribosome biogenesis and promote cellular growth and
proliferation, for example by cellular energy, nutrient and growth factor
sensing signaling pathways; or those that downregulate ribosome
biogenesis and prevent growth and proliferation in response to
challenges such as metabolic or genotoxic stress, or senescence signaling
pathways (Fig. 2). Signiﬁcantly, these pathways inherently contain
oncogenes and tumor suppressors, and their dysregulation enables cells
to achieve the uncontrolled growth and proliferation that is a hallmark
of cancer.
3. The nucleoli in cancer
Almost all cancer types display large and/or increased number of
nucleoli [27] (reviewed in [28]). In fact, nucleolar size can in some
cancers be used as a parameter for predicting clinical outcome, with
increased size corresponding to worse prognosis [29,30]. Changes in
nucleolar size have also been utilized as a measure of response to
chemotherapeutic drugs [31]. Consistent with the above, as nucleolar
size is related to its function in ribosome biogenesis, increased rates of
Pol I transcription are similarly observed in cancer and correlated with
adverse prognosis [32,33].
Perhaps somewhat surprisingly, the accelerated rates of rDNA
transcription associated with cancer do not appear to be due to “gain
of function” mutations in the Pol I apparatus, its associated factors or
other components involved in maturation and biogenesis of mature
ribosomes (reviewed in [34]). By contrast, loss of function mutations
in components of ribosome biogenesis have been extensively
reported, which collectively lead to the rare genetic diseases termed
Ribosomopathies (reviewed in [26]). Instead of “gain of function”
mutations, during malignant transformation rDNA transcription rates
are upregulated as the result of activation by oncogenic signaling, or
release from repression by tumor suppressor pathways, some of which
are described in more detail below.
3.1. Cell cycle regulatory proteins implicated in cancer
Dysregulation of cell cycle control is a common feature of most
cancer types (reviewed in [35]). Speciﬁcally, the CDK-cyclinD/INK4/
pRB/E2F pathway regulatingG1/S transition is commonly compromised
in cancer. The tumor suppressor retinoblastoma protein (pRb), when
active, prevents progression from G1 phase of the cell cycle (reviewed
in [36,37]). Mutation of the retinoblastoma gene (RB1) was ﬁrst identi-
ﬁed in retinoblastoma, however loss of pRb activity, such as by cyclin D
overexpression, CDK4 and CDK2 hyper-activation, or activation of
caspase dependent proteolytic pathways, is observed in most cancers
Fig. 1. Dynamic nucleolar structure. Non-malignant primary human T cells were grown under quiescent conditions (RP10 media) or under proliferative conditions (RP10 media with
5 ng/ml anti-CD28 in anti-CD3 coated wells). After PFA ﬁxation the nucleolar structure was visualized by ﬁbrillarin immunoﬂuorescence (red).
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UBF, preventing it from recruiting SL-1 to the PIC [39–41], and/or bind-
ing to the rDNA promoter [42]. Conversely, its negative regulators
CDK4-cyclin D and CKD2-cyclin E/A can enhance Pol I transcription
rates through activating phosphorylation of UBF [24,25].Fig. 2. The “inputs” and “outputs” of the nucleolus. The nucleolus is responsive tomultiple prolif
at the rDNA. Thus the nucleolus acts as a central integrator of signaling pathways, with its acti
drive ribosomebiogenesis, the nucleolus controls cell cycle regulation, DNA damage response, st
of the epigenome. Dysregulation of the nucleolus may corrupt these processes, and co
(adapted from #115).3.2. MYC
The transcription factorMYC (product of the c-MYC oncogene) is one
of themost frequently activated oncoproteins, overexpressed in ~50% of
all cancers (reviewed in [43,44]). MYC regulates transcription of a largeerative or stress signaling pathways, which can directly regulate rates of Pol I transcription
vity determined by the overall status of the cell. In addition to responding to signaling to
ress response, senescence, telomere biogenesis, RNA andRNP biogenesis, and organization
nsequently drive tumorigenesis through the acquisition of key hallmarks of cancer
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key factors involved in ribosome biogenesis and protein synthesis
[45,46] (reviewed in [47–50]). MYC modulates Pol I transcription in
multiple ways: it upregulates transcription of core Pol I subunits and
transcription factors (such as UBF and RRN3) [51–53]; while directly,
it associates with SL-1 to stabilize the UBF/SL1 complex, and binds to
the rDNA to promote Pol I recruitment [54–56]. In addition, MYC pro-
motes transcription of factors required for rRNAmaturation and assem-
bly [57,58], 5S rRNA by Pol III [59], and the RP genes by Pol II. Thus, MYC
acts as a master regulator of ribosome biogenesis (reviewed in [60,61]).
3.3. RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways
The most prominent growth/nutrient regulatory pathways known
to modulate Pol I transcription are the RAS/RAF/MEK/ERK and PI3K/
AKT/mTOR signaling cascades. The RAS/RAF/MEK/ERK pathway can
regulate Pol I transcription via multiple kinases, including ERK, MAPK,
RSK2, and JNK [62–64] (reviewed in [20]). For example, ERK directly
phosphorylates, and thus activates: i) UBF to increase Pol I transcription
elongation [21,65] and ii) RRN3 to promote Pol I initiation [63]. PI3K/
AKT/mTOR/S6K pathway components modulate the activity of Pol I
through, for example: ribosomal protein S6 kinase (S6K), which
indirectly modulates UBF and RRN3 phosphorylation, thus enhancing
Pol I transcription [66,67]; PTEN, an upstream negative regulator of
PI3K/AKT/mTOR, which represses Pol I transcription by promoting
dissociation of the SL-1 complex [68]; or AKT, which is able to activate
Pol I transcription at multiple levels [69]. Further, both pathways
cooperate with MYC: ERK stabilizes MYC by phosphorylation [70],
while AKT cooperates with MYC to activate Pol I transcription [69].
Numerous components of these signaling cascades act as oncoproteins,
amplifying proliferative signaling down their respective pathway. For
example, RAS and RAF are mutated in 30% and 6–7% of human cancers
respectively (reviewed in [71–73]). PTEN expression is reduced in a
range of cancers, the result of which is enhanced PI3K signaling
(reviewed in [74,75]). In the PI3K pathway itself, the PIK3CA catalytic
subunit of PI3K is most commonly reported to be ampliﬁed or mutated,
while for a smaller subset of cancers other molecules including AKT,
4EBP1, eIF4E, Rheb and S6K1 are overexpressed and/or hyperactivated
[76–78] (reviewed in [79,80]).
3.4. p53
The archetypal tumor suppressor p53 is assigned the title of “guardian
of the genome”, due to its role as a key mediator of stress signaling
responses, including cell cycle arrest, senescence and apoptosis. The
diverse roles bywhich p53 has been reported to perform tumor suppres-
sive functions are too extensive to be discussed here, but have been
covered in a number of in depth reviews [81–83]. Correspondingly, p53
is mutated in approximately half of all human tumors [84], and in the
majority of remaining tumors expressing wild-type p53 its function
is compromised. p53 directly inhibits Pol I transcription by binding to
SL-1, thus preventing its interaction with UBF and formation of the PIC
[85]. Further, downstream targets of p53-dependent stress signaling
also negatively regulate Pol I transcription, including activation of pRb
(reviewed in [86]), or repression of MYC [87].
3.5. ARF
In response to aberrant growth or oncogenic stress, the tumor
supressor p14ARF engages anti-proliferative pathways. Its best character-
ized function is as a key regulator of p53, resulting in p53 stabilization and
activation [88] (reviewed in [89]), but it can also act independently of p53
to induce cell cycle arrest or apoptosis [90,91] (reviewed in [89]). Loss of
p14ARF is almost as common as loss of p53, occurring in as many as 40%
of human cancers (reviewed in [92,93]). ARF can directly repress Pol I
transcription via altering UBF phosphorylation and hence its ability torecruit the PIC, and also prevent Pol I transcription termination factor
(TTF-1) nucleolar import [94] and [95].
In addition to the well-known pathways discussed here, numerous
other oncoproteins and tumor suppressors have also been convincingly
shown tomodulate Pol I transcription. These include, for example, ATM,
ATR and DNA-PK [96–98], CK2 [99–101], AML-ETO [102], RUNX2
[103–105], and NPM [106], (reviewed in [26]). Also, the recent use of
‘omics’ technologies has enabled the identiﬁcation of many possible
new components including, for example, deltaN isoform of netrin-1
[107], DDX31 [108], and ZNF545/ZFP82 [109].
Importantly, the above examples consistently demonstrate that
ribosome biogenesis is directly targeted by pathways that drive the
process of transformation. Such hijacking of the nucleoli is necessary
to enable increased rates of protein synthesis and cell growth that are
characteristic of cancer. However, the extent to which changes in
ribosome number actually contribute to transformation, rather than
being merely a reﬂection of the transformed phenotype, had not until
recently been tested. Now though, there is strong evidence to suggest
that accelerated ribosome biogenesis is both necessary for, and a driver
of, the malignant phenotype [1]. Most intriguingly, it appears that it
is the additional functions of the nucleolus that are corrupted by
the accelerated ribosome biogenesis, independent of changes in cell
capacity for protein synthesis, and are the critical determinant of
malignant transformation.
4. Extra-ribosomal nucleolar functions and cancer?
There is now overwhelming evidence that the nucleolus has extra-
ribosomal functions, which add an additional layer of complexity to
the relationship between dysregulated ribosome biogenesis and cancer.
In particular, recent advances in proteomic analysis of the nucleolus
have demonstrated its plurifunctional nature [110–114]. Of the over
4500 proteins reported in the nucleolar protein database (NOPdb)
(http://lamondlab.com/NOPdb3.0/), less than half have deﬁned func-
tions in ribosome biogenesis. Rather, proteins that localize to the nucle-
olus are involved in a diverse range of functions including regulating
tumor suppressor and proto-oncogene activities, cell-cycle control,
DNA replication and repair, and stress signaling. Importantly, dysregula-
tion of many of these processes is known to drive malignant transfor-
mation [115].
Critically, the nucleolar proteome is not static, but dynamically
altered in response to physiological and pathological signals such as
nutrient and growth factor signaling or stress [116–120]. Rather than
a consequence of passive diffusion, nucleolar residence of many
proteins is regulated through controlled sequestration and release
[121–128]. It follows that perturbations in nucleolar function and struc-
ture will lead to disruption of this regulation by nucleolar localization
and as a consequence affect multiple cellular functions. Indeed it is
apparent that many of the very same pathways containing oncogenes
and tumor suppressors that modulate Pol I transcription during tumor-
igenesis (see Section 3), are themselves subject to regulation by the
nucleolus. Thus the nucleolus is both the target of cancer signaling and
also functions as an upstream regulator of pathways important for
cancer. This homeostatic feedback loop clearly positions the nucleolus
as central to the processes that are known to drive the hallmarks of
cancer. Overcoming the ability of the nucleolus to correctly mediate
these additional functions increasingly appears to be a key permissive
step for malignant transformation and is described in more detail
below (Fig. 2).
4.1. Nucleolar regulation of p53
A key function of the nucleolus that relates to cancer is its role in
the regulation of the tumor suppressor p53. Typically p53 protein is
maintained at basal levels in the cell by MDM2, which inhibits p53
activity by two mechanisms: i) ubiquitination, which targets it for
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transactivation activity. In order to stabilize and activate p53, it must
be released from inhibitory association with MDM2. Further, post-
translational modiﬁcation and association with co-factors mediate p53
activity towards its transcriptional targets (reviewed in [129,130]). It
is now clear that activation of p53 and its tumor suppressor function
is mediated, in part, by the nucleolus. This is achieved throughmultiple
mechanisms including the NPM1-MDM2-p14ARF axis, the RP-MDM2
nucleolar stress pathway, and via regulation of p53 trafﬁcking.
4.1.1. NPM1-p14ARF-MDM2
The predominantly nucleolar protein, p14ARF binds MDM2 and
inhibits its activity toward p53. Under normal conditions p14ARF is
maintained at low levels by ubiquitin-mediated degradation, however
it is transcriptionally upregulated and stabilized by the multifunctional
nucleolar chaperone protein nucleophosmin (NPM1) in response to a
variety of signals, particularly oncogenic or genotoxic stress. Nucleolar
localization mediates the NPM1-p14ARF-MDM2-p53 pathway in two
ways: i) translocation of NPM1 from the nucleolus to the nucleoplasm
promotes the interaction of p14ARF with MDM2, thus disrupting
MDM2's association with p53 and subsequent degradation of p53
[131-133], ii) increased nucleolar localization of p14ARF may result in
its further stabilization, by preventing its degradation, as well as poten-
tially sequester MDM2 from p53 [134] (reviewed in [129]).
4.1.2. RP–MDM2 nucleolar stress pathway
Following abrogation of ribosome biogenesis – for example, by
inhibition of rDNA transcription or disruption of the 40S and 60S
ribosomal subunit biogenesis – several RPs are released from the nucle-
olus, which bind MDM2 and inhibit its ubiquitin ligase activity towards
p53, resulting in p53 accumulation (Fig. 3). These include RPs L5, L11,
L23, L26, L37, S7, S15 and S20, although the best characterized and
most robust data suggests RPL5 and RPL11 are the most important
[135–146]. Upon nucleolar stress, RPL5 and RPL11 together with 5S
rRNA are mutually stabilized, and as part of the RPL5/RPL11/5S rRNA
complex bind MDM2 inhibiting both its E3 ligase function and its
association with p53 [147–149]. This nucleolar stress pathway appears
to be regulated at a number of levels, for example RPL11 can be seques-
tered in the nucleolus by factors such as PICT1 [123], or through post-
translation modiﬁcation by NEDD8, the inhibition of which promotes
association with MDM2 [150,151,128]. Importantly, the requirement
of RP binding to MDM2 in p53 activation by nucleolar stress has been
substantiated in an in vivo mouse model [152].
Additional nucleolar factors also regulate p53 under conditions of
nucleolar stress, either by stabilization as described above, or by alterna-
tive mechanisms (Fig. 3). For example, p53 mRNA is stabilized by the
multifunctional nucleolar protein nucleolin (NCL) and RPL26, which
bind to the 5′UTR of p53 mRNA and mediate increased p53 translation
[153]. Interestingly under normal conditions, MDM2 targets RPL26 for
degradation; thus decreased MDM2 activity following nucleolar stress
would result in RPL26 stabilization and further increase p53 translation
and abundance [154]. A number of proteins can dissociate the interac-
tion between p53 andMDM2, thus resulting in p53 stabilization. For ex-
ample RPS3 directly interacts with p53 [155], while Nucleostemin can
bind directly to MDM2 [156,157]. Further, NCL associates with both
p53 and MDM2, and depending on post-translational regulation can
either antagonize their interaction or promote p53 degradation
[121,158,159]. Finally, p53 transcriptional activity is mediated by acety-
lation by its coactivator p300/CBP; this is facilitated by neddylated
RPL11 and MYBBP1A, which is sequestered in the nucleolus and
released upon nucleolar stress [160,161,151,162].
4.1.3. p53 trafﬁcking
In addition to sequestration of factors that regulate p53, the
nucleolus may play a direct role in p53 transport and its degradation
[163]. Both MDM2 and ubiquitinated p53 trafﬁc through the nucleolus,and this may be required for the cytoplasmic export and subsequent
degradation of p53. If p53 andMDM2 are co-transported with ribosomal
subunits, then disruption of ribosome biogenesis could result in p53
accumulation, in part due to abrogation of this process sequestering p53
away from the proteasome [164–166,163].
The varied mechanisms by which the nucleolus and its components
modulate p53 activity are indicative of its importance to the fundamental
cellular p53 response. Further, p53 and its downstream targets can
negatively regulate rDNA transcription (see Section 3) resulting in
a feedback loop enhancing p53 regulation by the nucleolus. In fact,
proteomic analysis of p53 wild-type compared to p53 null cell lines
(HCT116) demonstrated that the population of proteins that translocate
from the nucleolus upon nucleolar stress, including the RPs, is markedly
different when p53 is absent [167]. Thus the nucleolus is potentially the
focal point for the integration of multiple stress signals, enabling it to
mediate an appropriate p53 response. While such surveillance and
regulation is potentially critical for the prevention of cancer, until recent-
ly, data supporting a role for ribosome biogenesis in the promotion of
tumor development through suppression of p53 function was largely
circumstantial. Donati et al. demonstrated that upregulation of rRNA
transcription in human cancer cell lines in vitro, and a regenerating rat
liver model in vivo, decreased the p53 response to cytotoxic stress [10].
Macias et al. also reported that mice expressing an MDM2 mutant that
no longer binds RPL5 or L11, exhibited earlier onset and more frequent
tumors when crossed with Eμ-MYC transgenic mice compared to
MDM2 wild-type mice [152]. These ﬁndings support a model where,
under conditions of hyperactivated rDNA transcription, nucleolar compo-
nents that mediate p53 signaling (such as RPs) are constantly consumed
by the process of ribosome biogenesis, preventing p53 activation.
4.2. Nucleolar regulation of the cell cycle
While nucleolar control of cell cycle progression is exempliﬁed by
induction of a p53-mediated cell cycle arrest following inhibition of
rDNA transcription, the nucleolus additionally canmediate the function
of many other cell cycle regulatory proteins. For example, p14ARF
regulates the activity of a number of genes involved in cell growth and
proliferation, and can sequester cell cycle regulatory proteins in the
nucleolus in response to cellular stress and inhibit cell cycle progression
[91,168,124] (reviewed in [89]). On the other hand, NCL translocates
from the nucleolus in response to stress, where it interacts with replica-
tion protein A (RPA) thus preventing activation of DNA replication
[169,121]. Cyclin E, which is essential for DNA replication in S phase, is
rapidly inactivated by nucleolar sequestration where it is ubiquitinated
by nucleolar SCFFbw7gamma [127]. Interestingly, Fbw7 mediates the
turnover of numerous proteins required for growth and proliferation
(such as MYC), suggesting that a similar mechanism of nucleolar
sequestration may be employed to rapidly inactivate these proteins also.
Finally, Cdc14B is sequestered in the nucleolus during interphase, and
then released at mitosis to regulate correct mitotic progression [170].
Correct duplication of the centrosome and chromosome segregation
is an essential process during the cell cycle, especially critical for
genomic stability. A number of nucleolar factors are reported tomediate
this process including: i) NPM1 and NCL, which associate with the
mitotic poles, and mediate correct centrosome duplication and forma-
tion of the mitotic spindle [171–173]; ii) HCA66, which is a component
of the centrosome required for both centriole duplication and formation
of themitotic spindle, also localizes to the nucleolus in interphase and is
required for maturation of the 40S ribosomal subunit [174]; and iii)
RPL41, which associates with the microtubules during mitosis and is
required for centrosome integrity [175].
Nucleolar control of the cell cycle requires its appropriate assembly
and functional regulation throughout the processes of cell replication
and division (see Section 2). Aberrant functioning of the nucleolus
therefore has the potential to compromise both cell cycle processes,
such as correct DNA replication and mitosis, and the checkpoints that
Fig. 3. The nucleolar stress pathway. Under normal growth conditions, levels of tumor suppressor p53 are suppressed by MDM2 binding leading to ubiquitination and degradation
of p53. Upon nucleolar stress, nucleolar factors, including ribosomal proteins (RPs) and rRNAs are released from the nucleolus into the nucleoplasm and cytoplasm. Ribosomal proteins
(predominantly L5 and L11) and 5S rRNA bind directly to MDM2, thereby releasing p53 allowing the tumor suppressor to accumulate. In addition, p53 mRNA expression has been
shown to be upregulated by free ribosomal protein L26. The resultant activation of the p53 pathway can lead to cell cycle arrest, senescence or apoptosis.
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cancer [115].
4.3. Nucleolar regulation of the DNA damage response
Genome integrity is monitored by the DNA damage response (DDR)
network, which activates cell cycle checkpoints and DNA repair
pathways in response to speciﬁc types of DNA lesions. Compromised
DDR results in genomic instability, a key underlying cause of cancer. At
the nucleolus, DNA damage results in inhibition of rDNA transcription
and reorganization of nucleolar structure [96,176,119,97]. At the same
time, the nucleolus is increasingly reported to play an active role in theDDR. Proteomic and ﬂuorescent imaging analyses have shown not only
that a number of DDR proteins localize to the nucleolus, but that in
response to different genotoxic insults the nucleolus undergoes reorga-
nization with a distinct population of proteins translocating between
the nucleolus and the nucleoplasm [177,117,167,119]. For example,
double stranded break (DSB) repair factors RNF8 and BRCA1 translocate
from the nucleolus to DNA-damage response foci in the nucleoplasm
following ionizing radiation (IR), then revert to the nucleolus after several
hours, presumably following DSB repair [178]. NCL interacts with a
number of proteins involved in DNA repair (Topo I [179], Rad51 [180],
WRNp [181]), and relocalizes from the nucleolus to the nucleoplasm
where it associates with gamma-H2A.X and DDR foci [182]. Cdc14B is
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damage [122], leading to Cdc14B-induced activation of the G2–DNA
damage cell cycle checkpoint [170]. PARP-1 translocates from the
nucleolus to the nucleoplasm following DNA damage [183,119], where
it is involved in both DNA repair and induction of cell death; Notably,
delocalization of PARP-1 from the nucleolus, such as occurs during stress
response, sensitizes cells to DNA-damage induced apoptosis [183].
It has been proposed that as the rDNA repeats are particularly
vulnerable to genomic instability, due to their repetitive nature and
high rates of transcription [184], the nucleolus may activate DDR in a
highly sensitive manner, performing a protective function overall for
the genome [185]. To this end, Rubbi and Millner proposed that DNA
damage at the nucleolus, but not at nucleoplasmic DNA, is necessary
and sufﬁcient to activate p53-dependent DDR [186]. Importantly,
upregulated rRNA synthesis in different models was responsible
for both increased DNA damage at the rDNA [187], and decreased
p53-mediated response to cytotoxic stress [10]. This suggests that
nucleolar dysregulation may result in both genomic instability at the
rDNA repeats, and compromised DDR across the whole genome.
4.4. Nucleolar regulation of senescence
The activation of senescence, the process that drives a permanent
cessation of cell proliferation, is emerging as an important mechanism
for preventing or treating cancer (reviewed in [188]). Typically
senescence is seen as preventing both hyperproliferation and genomic
instability induced by telomere shortening, both of which are observed
in cancer [115]. The involvement of the nucleolus in senescence has
been clearly established, as inhibition of Pol I transcription induces
senescence in both immortalized and transformed human cell lines
[189] (reviewed in [190]).
The key signaling pathways mediating senescence include p53 and
p16INK4a-pRb (reviewed in [191]). Thus, the nucleolus may induce
senescence through its function in p53 pathway activation, discussed
above. In addition, pRb transiently localizes with the nucleolus and
nucleolar proteins, though the function of these associations in the
regulation of the pRb pathway is less well-deﬁned [41,192–194].
Nucleolar involvement in telomere stability ismediated by nucleolar
localization of components of telomerase, and the telomere binding
complex shelterin (reviewed in [190]). Telomerase is an RNP, composed
of an RNA component (TERC) and reverse transcriptase (TERT),
responsible for preventing telomere shortening during replication. In
early S-phase, TERT moves to the nucleolus while TERC accumulates in
Cajal bodies at the nucleolar periphery [195]. This nucleolar localization
may be a pre-requisite for telomerase biogenesis [196–198,195,199].
Shelterin modulates telomerase activity and protects telomeres
(reviewed in [200]). The shelterin component telomeric repeat binding
factor 2 (TRF2) localizes to the nucleolus duringG1 and S phase, and dif-
fuses to the nucleoplasm in G2 [201]. Another shelterin component
telomeric repeat binding factor 1 (TRF1) is stabilized or degraded by
nucleolar proteins nucleostemin (NS or GNL3) and GNL3L respectively
[202,203]. Telomere dysfunction, via loss of telomeric repeats or protec-
tive structures, triggers DDR at chromosome ends. This can lead to:
i) end-to-end fusions, thus gross chromosomal aberrations and changes
in ploidy; and eventually ii) the acquisition of new telomeres (reviewed
in [200]).
Nucleolar dysregulation may therefore facilitate malignant transfor-
mation through: a) an escape from the senescence signaling pathways;
b) driving genomic instability as a result of telomere dysfunction; and
c) ‘telomere healing’, as a result of continual rounds of DDR at telomeres,
enabling stable proliferation of malignant clones.
4.5. Nucleolar mediated epigenetic regulation of the genome
The organization of the genome within the nucleus contributes
to the regulation of physiological processes such as transcription,replication, and establishing chromatin. Particularly, the spatial localiza-
tion of chromosome regions can be required for the establishment of
heterochromatin states, and as such can both regulate expression and
maintain genomic integrity [204]. Recent genome wide analysis
classiﬁed approximately 4% of the genome, in addition to regions
containing NORs, as nucleolus-associated chromatin domains (NADs)
[205]. Chromosomal regions – including telomeric and centromeric
regions [206–208,205,209], satellite repeats [205], the Y chromosome
[210], the inactive X chromosome (Xi) [211], imprinted chromatin
regions [212,213], and repressed gene clusters speciﬁc to different cell
types [205] and [209] – can be constrained at the nucleolar periphery,
signifying a role for the nucleoli in organization of the genome
(reviewed in [214]). Common characteristics of NADs are repressive
histone marks and reduced gene expression; this includes repetitive
regions, regions with low gene density and regions enriched in
repressed genes [205,209]. In fact, the Xi is targeted to the perinucleolar
heterochromatin during its inactivation, and it is proposed that its
ongoing associationwith this region during S-phase is required tomain-
tain its heterochromatic state [211]. Additionally, depletion of Tip5, a
factor required for epigenetic silencing of the rDNA, resulted in loss of
repressive histone marks and destabilization not only at the rDNA but
also at associated satellite repeats [215]. Therefore, perinucleolar
heterochromatin is proposed to function in the maintenance of repres-
sive epigenetic state as a general strategy to prevent genomic instability.
Actively transcribed RNA pol III-dependent 5S and tRNA genes can
also be found at the nucleoli [205], and enrichment of such genes has
been documented in the perinucleolar regions surrounding the nucleo-
lus [216–219]. Interestingly, Pol III transcribed 5S rDNA genes can
induce association of the genomic region in which they are integrated
with the nucleoli. As non-coding repetitive elements derived from Pol
III transcripts make up a large proportion of the genome, it has been
proposed that these can signiﬁcantly contribute to nucleolar association
[220]. Importantly, this association can result in the repression of linked
genes, demonstrating the association between rRNA transcription,
nucleolar localization and regulation of gene expression [220]. Thus,
increased rDNA transcription could conceivably contribute to cellular
transformation through altered organization and epigenetic regulation
of the genome: Increased Pol I transcription as a result of loss of rDNA
silencing could correspond to reduced epigenetic silencing of other
NADs, resulting in genomic instability, particularly at repetitive regions;
altered association of genomic regions with the perinucleolar hetero-
chromatin may result in altered epigenetic regulation and expression
from a number of loci.
In conclusion, the nucleolus controls many cellular processes whose
dysregulation drive the acquisition of the hallmarks of cancer (Fig. 2).
For the nucleolus to properly regulate these functions it needs to be
exquisitely responsive to qualitative and quantitative changes in
cellular stress signals. However in cancer, acquired oncogenic drivers
(for example the overexpression of MYC), or loss of tumor suppressors
(for example p53) result in the consistent hyperactivation of rDNA
transcription. This effectively deadens nucleolar response to upstream
signaling, preventing appropriate regulation of both ribosome biogenesis
and extra-ribosomal nucleolar functions. Thus the nucleolus is a potential
target in cancer therapy, with the inhibition of rDNA transcription
predicted to not only reduce ribosomebiogenesis and the protein transla-
tion capacity of growing cancer cells, but also restore appropriate regula-
tion of many processes that are hurdles to acquisition of the cancer
phenotype, such as activation of p53.
5. Targeting the nucleolus in cancer
The concept of targeting the nucleolus and ribosome biogenesis in
cancer has proven to be controversial. This is due, in a large part, to its
essential housekeeping role in sustaining the proliferation of normal
cells. Thus it has been considered that drugs targeting ribosome biogen-
esis would not discriminate between highly proliferating normal cells
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the fact that it has been known for over two decades that a number of
conventional chemotherapeutic agents impair ribosome biogenesis
and/or nucleolar size, number and morphology [221–228]. A recent
screen of common chemotherapeutic drugs demonstrated that out of
36 agents tested, 21 were found to affect ribosome biogenesis at the
level of: (i) rDNA transcription, (ii) early rRNA processing (measured
by the occurrence of the 32S rRNA intermediate) and (iii) late rRNA
processing (measured by the occurrence of the mature 28S or 18S
rRNAs) [225]. Moreover, a nucleolar disruption phenotype, character-
ized by the mislocation of NPM1, was consistently associated with the
inhibition of rDNA transcription or early rRNA processing steps, but
not late rRNA processing steps [225].Fig. 4. Targeting the nucleolus in cancer therapy. A diverse range of anti-cancer drugs target rib
transcription andpre-rRNA processing, ormay impair the activity ofmembers of upstream signa
highlighted in red and underlined.While the drug screen of Burger et al. [225] did not demonstrate
whether the tested chemotherapeutic agents directly modulated the
Pol I transcriptional machinery or the various rRNA processing factors,
there is good evidence from a number of chemotherapeutics in current
clinical use that their therapeutic efﬁcacy is mediated in part by their
ability to directly inhibit ribosome biogenesis (Fig. 4). For example,
Dacitnomycin (also called Actinomycin D), a naturally occurring
polypeptide antibiotic that intercalates GC-rich regions of DNA, is highly
selective for the rDNA gene at concentrations as low as 5 nM and
prevents the elongation stage of rDNA transcription by Pol I (Figs. 4
and 5) [229]. In addition, the platinum-containing compound cisplatin
inhibits Pol I transcription with a high degree of speciﬁcity [221]
through its ability to cross-link DNA at HMG-protein afﬁnity sites thusosome biogenesis and nucleolar function. These agents can act directly at the level of rDNA
ling pathways that regulate ribosomebiogenesis and the nucleolus. Anti-cancer agents are
Fig. 5. Inhibition of RNA transcription by CX-5461 and Dactinomycin. Human ﬁbroblast immortalizedwith hTERTwere treated for 2 hwith either 5 nMDactinomycin or 1 μMCX-5461 to
selectively inhibit Pol I, orwith 4 μMDactinomycin to inhibit all three RNA Polymerases (Pol I, II and III). After 1 h of treatment, media containing 1 mMof ethynyl uridine (EU)was added
and the EU that had been incorporated into newly transcribed RNAwas conjugated toﬂuorescently-tagged sodiumazide by “click chemistry” {Jao, 2008#305} (green). Following selective
Pol I inhibition, no RNA is transcribed in the nucleolar regions as measured by EU staining.
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gene promoter [222]. Similarly, the anti-metabolite 5′ﬂuorouracil (5′
FU), a well-characterized inhibitor of nucleotide synthesis [230], dis-
rupts rRNA processing by preventing the cross-linking of rRNA binding
proteins at key processing sites of the precursor rRNA transcript
[223,224] (Fig. 4). In addition, inhibitors of Topoisomerase I activity, spe-
ciﬁcally Camptothecin, Irinotecan and Topotecian have also been demon-
strated to potently disrupt Pol I transcription [231,232] (reviewed in [6])
(Fig. 4). In particular the ellipticine drug family of planar alkaloids [233]
demonstrated anti-tumor activity in clinical trials [234–236] that was
historically proposed to be the result of DNA breakage following the
formation of an ellipticine–topoisomerase II–DNA ternary complex
[237]. Recently the ellipticine derivative 9-hydroxyellipticine (9HE) was
shown to speciﬁcally inhibit Pol I transcription by preventing the
interaction between SL-1 and the rDNA gene promoter [238] (Fig. 4).
Presumably 9HE via intercalating DNA at GC rich sites [239,240], which
are common to the rDNA gene promoter, promoted DNA unwinding
and the interruption of DNA-SL-1 interactions [238].
5.1. Nucleolar functions for targeted therapeutics
In addition to well-established conventional chemotherapeutic
agents, many emerging anti-cancer drugs have been demonstrated to
impair ribosome biogenesis in pre-clinical models. Various inhibitors
of protein kinases have been demonstrated to inhibit ribosomebiogenesis, in keeping with the regulation of this process by cellular
growth and proliferation signaling pathways. Chemotherapeutic inhib-
itors of protein kinases that regulate the progression of cells through the
cell cycle also disrupt ribosome biogenesis [225], consistent with the
well-documented link between cell cycle control and the nucleolus
(see Section 2). For example, the Cdk2 inhibitors roscovitine and
olomoucine and the casein kinase 2 (CK2) inhibitor 5,6-dichloro-1-
beta-ribofuranosylbenzimidazole (DRB) have been demonstrated to
disrupt nucleolar integrity and drive themislocalization of unprocessed
rRNAs and rRNA processing factors, while rRNA processing has been
demonstrated to be highly sensitive to the Cdk9 inhibitor Flavipiridol
[241–244] (Fig. 4). Rapamycin, a naturally occurring speciﬁc inhibitor
of the mammalian target of rapamycin complex 1 (mTORC1) is both
an anti-cancer and immunosuppressive agent, reviewed in [245]
(Fig. 4). Rapamycin has been well documented to suppress rDNA gene
transcription by impairing signaling downstream of mTORC1 [66,246]
and the new-generation ‘rapalog’ everolimus, which is FDA-approved
for the treatment of renal cell carcinoma and advanced ER-positive/
HER2-negative breast cancer [247,248], displays potent anti-tumor
activity in a MYC-driven lymphoma model characterized by enhanced
Pol I transcription [1,249]. Inhibitors of the protein kinase AKT, which
acts upstream of mTORC1 and has important roles for the control of
cell survival, proliferation, metabolism and angiogenesis, reviewed in
[250], also impair ribosome biogenesis with the allosteric pan-AKT
inhibitors AKTi-1/2 and MK-2206 demonstrated to suppress rDNA
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MYC-driven lymphoma (Eμ-MYC) in culture and in vivo respectively
[69,251] (Fig. 4).
5.2. Targeting the nucleolus by design: engineering speciﬁc inhibitors of
ribosome biogenesis
The recent reevaluation of the nucleolus as a target for cancer
therapy has been driven by our increased understanding of: (i) the
importance of ribosome biogenesis in malignant transformation;
(ii) the discovery of the nucleolar control of p53; and (iii) the inhibition
of ribosome biogenesis being identiﬁed as key features of many chemo-
therapeutic and anti-cancer drugs. In particular, the development of a
series of small molecules by Cylene Pharmaceuticals that speciﬁcally
target ribosome biogenesis at the level of rDNA gene transcription by
Pol I has met with some impressive success in identifying novel anti
cancer agents.
5.2.1. CX-3543 (quarﬂoxin)
The ﬁrst of the “selective Pol I transcription inhibitors” developed,
CX-3543 (quarﬂoxin) speciﬁcally inhibits the elongation stage of Pol I
transcription by preventing the stabilizing interactions between NCL
and G-quadruplexes in the rDNA gene [252] (Fig. 4). NCL, which
mediates the stabilization of G-quadruplex structures and prevents
the renaturation of template DNA in the GC-rich rDNA gene facilitating
rapid Pol I transcription [253], is selectively displaced from DNA by
CX-3543 resulting in its redistribution from the nucleolus to the
nucleoplasm and the inhibition of rDNA transcription [252]. ThisFig. 6. Pol I activity and nucleolar structure in response to CX-5461 treatment. Acute myeloid le
cells were assayed by RNA-FISH with a probe designed against the 47S pre-rRNA external tran
commonly used as a surrogate measure for Pol I activity (green, top panels). Also, the nucleolaactivity of CX-3543 is speciﬁc for NCL, with no observed impact on the
association of Pol I transcription factors, such as UBF and SL-1, with
the rDNA promoter, and was associated with the stabilization of p53
in keeping with the established nucleolar stress response discussed
above (see Section 4.1) [252]. In pre-clinical studies utilizing a panel
of cancer cell lines, CX-3543 exhibited a broad anti-proliferative effect
and induced apoptosis of cancer cells independent of their p53 status.
Furthermore CX-3543 demonstrated anti-tumor growth properties in xe-
nograft models of breast (MDA-MB-231) and pancreatic (MIA PaCa-2)
cancer [252] and progressed through a Phase I dose-escalation study in
advanced solid tumors [254] (ClinicalTrials.gov NCT00955786) and a
Phase II trial in low to intermediate grade neuroendocrine carcinoma
(ClinicalTrials.gov NCT00780663) but was withdrawn from further trials
due to issues with bioavailability [255].
5.2.2. CX-5461
The search for the next generation of direct Pol I inhibitors yielded
the lead compound CX-5461 (now owned by Senhwa Biosciences), a
small molecule that prevents PIC assembly by interfering with SL-1
binding to the rDNA promoter thereby preventing transcription
initiation [189] (Fig. 4). CX-5461 was shown to be a highly selective
inhibitor for Pol I activity, 300–400 folds more selective than for Pol II
or Pol III transcription (Figs. 5 and 6). Indeed CX-5461 demonstrated
limited direct effects on the transcription of Pol II target genes (c-MYC,
ACTB) or on DNA synthesis even at very high drug concentrations [189].
CX-5461 in vitro exhibited a high anti-proliferative efﬁcacy over
a broad panel of human cancer cell lines (at low nano-molar concentra-
tions) with a higher EC50 in non-cancer cell lines [189]. Robustukemia cells (KG-1 cells) were treated±500 nMCX-5461 for 4 h before PFA ﬁxation. The
scribed sequence (ETS) region which is rapidly processed following transcription, and is
r structure was visualized by ﬁbrillarin immunoﬂuorescence (red, bottom panels).
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(A375) and pancreatic (MIA PaCa-2) xenograft models, with CX-5461
inducing autophagy and senescence, in preference to apoptosis, in
solid tumor cells.
Subsequent studies with CX-5461 in mouse transgenic models of
hematologic malignancies have provided the best evidence to date
that accelerated rDNA transcription and nucleolar integrity are
critical for oncogenic activity tumor cells [1]. Speciﬁcally it was
demonstrated that Pol I transcription could be targeted in vivo to
selectively activate p53-dependent apoptosis in cancer cells, effec-
tively treating tumors in both genetically engineered and xenograft
models of lymphoma and leukemia [1]. Of particular interest, the in-
duction of p53 mediated apoptotic death of the hematologic tumor
cells was rapid, occurring within hours of treatment as a result of
nucleolar stress and was independent of changes in total ribosome
levels or protein translation. This observation is critical as it clearly
demonstrates that Pol I transcription and nucleolar integrity are acutely
required for the survival of certain tumor cells, independent of the
level of functional ribosomes and thus protein synthesis rates and cell
proliferation.5.3. What confers selectivity and sensitivity of drugs targeting
the nucleolus?
The above studies strongly suggest that cancers with altered genetic
programs driving enhanced rDNA transcription and ribosome biogenesis
will be vulnerable to the induction of a nucleolar stress response by
agents that target the nucleolus. Cancers characterized by c-MYC gene
ampliﬁcation or overexpression, are a key example of malignancies that
are likely to respond well to nucleolar-targeting agents. As mentioned
above, MYC has a broad transcriptional program that is geared towards
ongoing cell growth and proliferation, and through its ability tomodulate
the transcriptional activity of Pol I, Pol II and Pol III MYC acts as a global
regulator of ribosome biogenesis (see Section 3). Enhanced ribosome
biogenesis, characterized by increased rDNA transcription rates and Pol
I machinery abundance [1], is a key feature of transgenic Eμ-MYCmice
that constitutively overexpress MYC in B-lymphocytes and develop
aggressive B-lymphomas [256]. Consistent with the above hypothesis
that cancers characterized by oncogene driven up-regulation of ribosome
biogenesis should be vulnerable to Pol I inhibition, MYC driven Eμ-MYC
lymphomas are exquisitely sensitive to CX-5461. Indeed we believe
MYC overexpression alone, independent of transformation, can be
sufﬁcient to sensitize cells to Pol I inhibition, as pre-malignant Eμ-MYC
lymphoma cells demonstrated the samehigh sensitivity to Pol I inhibition
and apoptotic response as the fully malignant Eμ-MYC lymphoma
cells, despite exhibiting few genetic lesions in addition to elevated MYC
expression [1]. Moreover we have found that MYC overexpression but
not activation of other oncogenes such as RAS is sufﬁcient to increase sen-
sitivity to Pol I inhibition in human ﬁbroblasts (R. Hannan, unpublished
data).
Importantly, the apoptotic activity of CX-5461 in vivo was speciﬁc
for MYC overexpressing lymphoma cells with no deleterious effect on
the normal B-lymphocyte population observed in vivo [1]. This is
because the targeted inhibition of rDNA transcription in non-tumorigenic
B-lymphocytes in vivo by CX-5461 did not result in p53 pathway
activation or the induction of apoptosis, in contrast to genotoxic insults
such asγ-irradiationwhich activate DNAdamage andp53 in both normal
and tumor cells [1]. This ability of CX-5461 to induce p53-mediated
responses in a cancer-cell speciﬁc manner will be a major beneﬁt for
moving this agent into the clinic due to the absence of genotoxic
damage-associated side effects on the normal cell population. Finally, as
with any anti-cancer agent, the development of resistant disease is likely
to be an issue, and the potential combination of CX-5461 with conven-
tional and novel chemotherapeutic drugs or other targeted therapies
will be an important area to explore further.6. Conclusions
While traditionally the contribution of the nucleolus to tumorigenesis
has largely been seen to be centered on its role in facilitating ribosome
biogenesis and proliferative capacity, more contemporary studies dem-
onstrate the nucleolus is likely to play a much broader role in malignant
transformation. In particular, the extra-ribosomal functions of the nucle-
olus as a central integrator of cellular stress are emerging as newmecha-
nisms by which oncogenes and tumor suppressors can modulate
functions in normal and malignant cells. The high dependency of certain
tumor cells to co-opt nucleolar processes tomaintain their cancer pheno-
type has clearly been demonstrated by the application of small molecule
inhibitors of Pol I to selectively kill tumor cells in vivo [1]. Indeed it is like-
ly we have only begun to scratch the surface of the potential of the nucle-
olus as a new target for cancer therapy. In 2011 Hanahan and Weinberg
updated their “hallmarks of cancer” review [115]. It appears that “sup-
pressing nucleolar stress” deserves a place in the next iteration of this
classic text.
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